Decode Age, India's first longevity-focused company, has announced it has secured $1,700,000 in funding from investors. The capital injection marks a significant milestone for the company, which is dedicated to redefining the future of health by confronting ageing at its cellular level, aiming to extend healthspan rather than just lifespan.
The company operates an integrated ecosystem that merges cutting-edge science, biomarker testing, and evidence-based supplements. Decode Age addresses ageing, a common thread underlying over 90% of chronic diseases, by focusing on its root causes instead of merely treating symptoms. A multidisciplinary team of researchers, healthcare professionals, and technologists powers its efforts, translating breakthrough science into personalised longevity solutions. Offerings include gut microbiome tests and a curated portfolio of advanced nutraceuticals designed to track, improve, and optimise an individual's age.
This funding round is critical for Decode Age as it seeks to further solidify its pioneering position in the longevity sector. The company plans to use the funds to accelerate its research and development initiatives, expand its innovative product portfolio, and scale its operational footprint. This strategic investment will enable Decode Age to enhance its integrated offerings and reach a wider audience seeking proactive health solutions.
Looking ahead, Decode Age is committed to continuing its mission of building a movement around a new way of thinking about time, health, and potential. The company aims to further its leadership in extending healthspan, empowering more individuals to become "Longevian" as it scales its impact within India’s health and wellness landscape.
